This trial is active, not recruiting.

Condition non-small cell lung cancer
Treatment tissue collection
Sponsor Dartmouth-Hitchcock Medical Center
Start date July 2010
End date February 2017
Trial size 42 participants
Trial identifier NCT01510405, D1026


The investigators have characterized in preclinical Non-Small Cell Lung Cancer (NSCLC) models the proteomic expression profile associated with exposure to Aurora and Polo-like kinase inhibitors. The identification of proteomic expression patterns in patients with NSCLC would be an important step in defining the possible role of these agents as potential targeted therapies for this clinically important disease. This study proposes to evaluate resected non-small cell lung cancer specimens for these proteomic expression profiles.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
tissue collection Frozen tissue specimens will be stored at -80
Tissue sample collection

Primary Outcomes

Correlation between the Phosphoproteomic expression pattern of specific substrates of Aurora Kinase A and/or Polo-like kinase 1 (PLK1)
time frame: 2 years

Secondary Outcomes

Phosphoproteomic Expression Profiles and Correlated Global Phosphoproteomics Expression patterns
time frame: 2 years
Time to Disease Recurrence
time frame: 2 years
Lung Cancer Specific Survival
time frame: 2 years
Overall Survival
time frame: 2 Years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Subjects undergoing or who have undergone thoracic surgery for presumed lung cancer - Wedge resection, lobectomy, bilobectomy, segmentectomy and pneumonectomy thoracic surgical operations are permitted. - Age ≥ 18 years. - Subject meets criteria for thoracic surgery as determined by the thoracic surgeon. - Able to provide written informed consent. Exclusion Criteria: - Subjects undergoing or who have undergone thoracic surgery for metastatic disease from other primary sources such as colorectal cancer, sarcoma, melanoma, breast cancer, bladder cancer, prostate cancer, esophageal cancer, pancreatic cancer, or gastric cancer will be excluded. - Subjects who have received prior preoperative lung cancer anticancer therapy will be excluded.

Additional Information

Official title Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer
Principal investigator James R Rigas, MD
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center.